Genmab Q1 2026 operating profit fell to $180M despite 25% revenue growth, driven by Merus acquisition costs and commercial...

BridgeBio reports $180.6M Attruby revenue in Q1 2026, funding three simultaneous pipeline expansions with real-world evidence driving market share...

FDA's May 2026 approval of Veppanu, the first PROTAC drug, validates targeted protein degradation as a platform — and...

Genmab's Q1 2026 revenue rose 25% driven by DARZALEX royalties, but operating costs accelerate as pipeline candidates await launch.

Crinetics Palsonify revenue doubles sequentially in Q1 2026, reaching $10.3M with 70% of patients on reimbursed therapy.

Ascendis Pharma posts €197M YORVIPATH revenue in Q1 2026, more than doubling year-over-year company revenue despite cash position pressures.

Iovance advances three Phase 3 trials underway in endometrial cancer, NSCLC, and sarcoma while Q1 revenue grows 45% year-over-year...

BridgeBio Reports $180.6M Attruby Revenue in Q1 2026, with three NDAs pending and $940M cash reserves intact.

AstraZeneca's tozorakimab hit dual Phase III endpoints in COPD via OBERON and TITANIA, targeting a $1.68B biologic market with...

Pathos AI acquires DeuterOncology's MET inhibitor DO-2, a deuterated candidate showing 100% tumor shrinkage and 5% peripheral edema in...